Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use

Exclusion Criteria

• •Type 1 diabetes mellitus
• •Gestational diabetes mellitus
• •History of pancreatectomy
• •Continuous or intermittent insulin therapy for 7 days or more within 3 months
• •Oral or IV steroid treatment within 1 month prior to informed consent
• •Serious infection, surgery (scheduled or history), or severe trauma within 3 months prior to informed consent
• •History of malignancy within 1 year prior to informed consent (except thyroid cancer)
• •On hemodialysis or peritoneal dialysis or eGFR \< 30 mL/min/1.73m2
• •Unable to avoid the following concomitant medications, devices, or treatments during the study: CGM other than study device, X-ray/MRI/CT scans, radiofrequency thermal therapy, implantable devices such as pacemakers, immunosuppressants, steroids, IV vitamin preparations, cancer treatment, hemodialysis/peritoneal dialysis, insulin therapy
• •Uncontrolled thyroid disease or clinically significant severe endocrine disorders (Cushing's syndrome, pheochromocytoma, etc.)
• •Severe allergic reaction to skin adhesives (e.g., dyspnea, severe rash, edema)
• •Whole blood donation within 60 days, apheresis within 30 days, or blood transfusion within 90 days prior to device application
• •Judged by investigator as unable to handle continuous glucose monitoring device
• •Pregnant or lactating women
• •Planning pregnancy within 1 year
• •Otherwise judged by investigator as inappropriate for participation in this clinical trial